M Hu1, X Zong1, J Zheng2, J J Mann3, Z Li1, S P Pantazatos4, Y Li2, Y Liao1, Y He1, J Zhou1, D Sang5, H Zhao5, J Tang1, H Chen2, L Lv6, X Chen1. 1. Mental Health Institute of the Second Xiangya Hospital,Central South University,139 Middle Renmin Road,Changsha,Hunan 410011,People's Republic of China. 2. Key Laboratory for NeuroInformation of the Ministry of Education,School of Life Science and Technology,University of Electronic Science and Technology of China,Chengdu 610054,People's Republic of China. 3. Division of Molecular Imaging and Neuropathology,New York State Psychiatric Institute and Departments of Psychiatry and Radiology,Columbia University,1051 Riverside Drive,Box 42,New York,NY 10032,USA. 4. Division of Molecular Imaging and Neuropathology,New York State Psychiatric Institute and Departments of Psychiatry,Columbia University,New York, NY 10032,USA. 5. Department of Radiology,Henan Mental Hospital, the Second Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan 453002,People's Republic of China. 6. Department of Psychiatry,Henan Mental Hospital, the Second Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan 453002,People's Republic of China.
Abstract
BACKGROUND: It remains unclear whether the topological deficits of the white matter network documented in cross-sectional studies of chronic schizophrenia patients are due to chronic illness or to other factors such as antipsychotic treatment effects. To answer this question, we evaluated the white matter network in medication-naive first-episode schizophrenia patients (FESP) before and after a course of treatment. METHOD: We performed a longitudinal diffusion tensor imaging study in 42 drug-naive FESP at baseline and then after 8 weeks of risperidone monotherapy, and compared them with 38 healthy volunteers. Graph theory was utilized to calculate the topological characteristics of brain anatomical network. Patients' clinical state was evaluated using the Positive and Negative Syndrome Scale (PANSS) before and after treatment. RESULTS: Pretreatment, patients had relatively intact overall topological organizations, and deficient nodal topological properties primarily in prefrontal gyrus and limbic system components such as the bilateral anterior and posterior cingulate. Treatment with risperidone normalized topological parameters in the limbic system, and the enhancement positively correlated with the reduction in PANSS-positive symptoms. Prefrontal topological impairments persisted following treatment and negative symptoms did not improve. CONCLUSIONS: During the early phase of antipsychotic medication treatment there are region-specific alterations in white matter topological measures. Limbic white matter topological dysfunction improves with positive symptom reduction. Prefrontal deficits and negative symptoms are unresponsive to medication intervention, and prefrontal deficits are potential trait biomarkers and targets for negative symptom treatment development.
BACKGROUND: It remains unclear whether the topological deficits of the white matter network documented in cross-sectional studies of chronic schizophreniapatients are due to chronic illness or to other factors such as antipsychotic treatment effects. To answer this question, we evaluated the white matter network in medication-naive first-episode schizophreniapatients (FESP) before and after a course of treatment. METHOD: We performed a longitudinal diffusion tensor imaging study in 42 drug-naive FESP at baseline and then after 8 weeks of risperidone monotherapy, and compared them with 38 healthy volunteers. Graph theory was utilized to calculate the topological characteristics of brain anatomical network. Patients' clinical state was evaluated using the Positive and Negative Syndrome Scale (PANSS) before and after treatment. RESULTS: Pretreatment, patients had relatively intact overall topological organizations, and deficient nodal topological properties primarily in prefrontal gyrus and limbic system components such as the bilateral anterior and posterior cingulate. Treatment with risperidone normalized topological parameters in the limbic system, and the enhancement positively correlated with the reduction in PANSS-positive symptoms. Prefrontal topological impairments persisted following treatment and negative symptoms did not improve. CONCLUSIONS: During the early phase of antipsychotic medication treatment there are region-specific alterations in white matter topological measures. Limbic white matter topological dysfunction improves with positive symptom reduction. Prefrontal deficits and negative symptoms are unresponsive to medication intervention, and prefrontal deficits are potential trait biomarkers and targets for negative symptom treatment development.
Entities:
Keywords:
First-episode schizophrenia; longitudinal studies; networks; schizophrenia; topology; white matter
Authors: Andrew Zalesky; Alex Fornito; Marc L Seal; Luca Cocchi; Carl-Fredrik Westin; Edward T Bullmore; Gary F Egan; Christos Pantelis Journal: Biol Psychiatry Date: 2010-10-29 Impact factor: 13.382
Authors: Beth E Snitz; Angus MacDonald; Jonathan D Cohen; Raymond Y Cho; Theresa Becker; Cameron S Carter Journal: Am J Psychiatry Date: 2005-12 Impact factor: 18.112
Authors: Nicoletta M J van Veelen; Matthijs Vink; Nick F Ramsey; Mariët van Buuren; Janna Marie Hoogendam; René S Kahn Journal: Schizophr Res Date: 2011-04-15 Impact factor: 4.939
Authors: Wendy R Kates; Amy K Olszewski; Matthew H Gnirke; Zora Kikinis; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Petya D Radoeva; Frank A Middleton; Martha E Shenton; Ioana L Coman Journal: Schizophr Res Date: 2014-07-25 Impact factor: 4.939
Authors: Guusje Collin; René S Kahn; Marcel A de Reus; Wiepke Cahn; Martijn P van den Heuvel Journal: Schizophr Bull Date: 2013-12-02 Impact factor: 9.306
Authors: Johanna Seitz-Holland; Suheyla Cetin-Karayumak; Matcheri Keshavan; Marek Kubicki; Joanne D Wojcik; Amanda Lyall; James Levitt; Martha E Shenton; Ofer Pasternak; Carl-Fredrik Westin; Madhura Baxi; Sinead Kelly; Raquelle Mesholam-Gately; Mark Vangel; Godfrey Pearlson; Carol A Tamminga; John A Sweeney; Brett A Clementz; David Schretlen; Petra Verena Viher; Katharina Stegmayer; Sebastian Walther; Jungsun Lee; Tim Crow; Anthony James; Aristotle Voineskos; Robert W Buchanan; Philip R Szeszko; Anil K Malhotra; Yogesh Rathi Journal: Mol Psychiatry Date: 2021-01-22 Impact factor: 13.437